AstraZeneca PLC AZN

Morningstar Rating
GBX 11,946.00 +146.00 (1.24%)
View Full Chart

Company Report

Price vs Fair Value

AZN is trading within a range we consider fairly valued.
Price
GBX 11,800.00
Fair Value
GBX 69,333.00
Uncertainty
Medium
1-Star Price
GBX 81,449.00
5-Star Price
GBX 7,642.00
Economic Moat
Pbkxf
Capital Allocation
Yhgzynjzl

Bulls Say, Bears Say

Bulls

The company is expanding its oncology presence with several important pipeline products. In particular, the company's EGFR drug Tagrisso looks well positioned to drive major cash flows over the next decade.

Bears

The company's strong entrenchment in respiratory disease could cause challenges, as pricing power in this market tends to be weak.

News

Trading Information

Previous Close Price
GBX 11,800.00
Day Range
GBX 11,800.0012,010.00
52-Week Range
GBX 9,461.0013,388.00
Bid/Ask
GBX 11,500.00 / GBX 12,592.00
Market Cap
GBX 18.52 Tril
Volume/Avg
2.1 Mil / 1.8 Mil

Key Statistics

Price/Earnings (Normalized)
20.58
Price/Sales
4.72
Dividend Yield (Trailing)
1.98%
Dividend Yield (Forward)
1.98%
Total Yield
1.98%

Company Profile

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Growth
Total Number of Employees
89,900

Competitors

Valuation

Metric
AZN
LLY
PFE
Price/Earnings (Normalized)
20.5879.8420.99
Price/Book Value
5.8659.161.85
Price/Sales
4.7220.692.91
Price/Cash Flow
21.8980.2221.20
Price/Earnings
AZN
LLY
PFE

Financial Strength

Metric
AZN
LLY
PFE
Quick Ratio
0.690.610.51
Current Ratio
0.891.110.86
Interest Coverage
5.4515.08−0.88
Quick Ratio
AZN
LLY
PFE

Profitability

Metric
AZN
LLY
PFE
Return on Assets (Normalized)
57.63%13.15%3.50%
Return on Equity (Normalized)
151.23%69.16%8.28%
Return on Invested Capital (Normalized)
84.88%23.97%5.39%
Return on Assets
AZN
LLY
PFE

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
VmshyqltzvYkq$802.3 Bil
Johnson & Johnson
JNJ
YntpqdjwZdysn$388.0 Bil
AbbVie Inc
ABBV
FqrpyvlqXrcg$347.7 Bil
Merck & Co Inc
MRK
RjntdyxrrCzkj$284.1 Bil
Roche Holding AG ADR
RHHBY
SyxqkrmqDystk$252.2 Bil
AstraZeneca PLC ADR
AZN
LzspqqxrqQbqht$244.7 Bil
Novartis AG ADR
NVS
XfwkkfnhZtj$232.6 Bil
Amgen Inc
AMGN
HncznpkwcmZxyzd$171.8 Bil
Pfizer Inc
PFE
MfjflhbsdJvfvr$162.1 Bil
Sanofi SA ADR
SNY
BlglcvftdZnsg$145.1 Bil

Sponsor Center